Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RALES, EPHESUS and redox.

John W Funder1

  • 1Prince Henry's Institute of Medical Research, P.O. Box 5151, Clayton 3168, Vic., Australia. john.funder@phimr.monash.edu.au

The Journal of Steroid Biochemistry and Molecular Biology
|April 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Who and How Should We Screen for Primary Aldosteronism?

Hypertension (Dallas, Tex. : 1979)·2023
Same author

Recognising primary aldosteronism as a disorder in its own right.

The Medical journal of Australia·2023
Same author

Primary Aldosteronism: Imaging vs. Lateralization.

American journal of hypertension·2022
Same author

Primary Aldosteronism: Where Are We Now? Where to From Here?

Hypertension (Dallas, Tex. : 1979)·2022
Same author

Primary Aldosteronism: Three Strikes and Out.

Hypertension (Dallas, Tex. : 1979)·2021

Mineralocorticoid receptor (MR) antagonists like spironolactone improve survival in heart failure. These drugs may block cortisol, not just aldosterone, offering broader cardiovascular therapeutic potential.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Mineralocorticoid receptor (MR) antagonists, such as spironolactone, significantly improve outcomes in severe heart failure.
  • While aldosterone excess is a known detrimental factor, MR antagonists show benefits even with normal aldosterone levels.
  • Evidence suggests cortisol can activate MR in cardiovascular tissues, particularly with oxidative stress.

Purpose of the Study:

  • To investigate the mechanism behind MR antagonist efficacy in heart failure, especially when aldosterone levels are normal.
  • To explore the role of cortisol in activating MR in cardiovascular tissues.
  • To determine the potential for MR antagonists in a wider range of cardiovascular diseases.

Main Methods:

  • Review of clinical trial data (RALES, EPHESUS) on MR antagonist use in heart failure.

Related Experiment Videos

  • Analysis of animal studies investigating MR antagonists and vascular inflammation.
  • Examination of cellular mechanisms involving cortisol, reactive oxygen species (ROS), and MR activation.

    • Main Results:

    • Spironolactone improved survival by 30% and reduced hospitalizations by 35% in severe heart failure patients.
    • MR blockade prevented inflammatory responses in animal models, irrespective of aldosterone levels.
    • Cortisol, in conjunction with ROS or altered redox status, can activate MR in cardiac and vascular cells.

    Conclusions:

    • MR antagonists may exert therapeutic effects by blocking cortisol-mediated MR activation, not solely aldosterone.
    • This mechanism suggests broader applications for MR antagonists beyond conditions of aldosterone excess.
    • Further research is needed to understand the role of MR in tissues like cardiomyocytes and neurons under altered redox conditions.